Alphatec Holdings, Inc. (ATEC)

Alphatec Holdings, Inc. experienced several stock events in the past six months (August 2025 - February 2026). In Q3 2025, Alphatec reported earnings per share (EPS) of $0.03, exceeding analysts' estimates and raised its full-year guidance. Preliminary 2025 results showed revenue growth of approximately 25% to $764 million, but the 2026 revenue growth guidance of approximately 17% disappointed investors, leading to a stock price drop. There have been several instances of insider selling. Alphatec has received an average recommendation of "Moderate Buy" from analysts, with a high percentage of "Strong Buy" ratings and an average 12-month target price of approximately $22.82. Alphatec announced a strategic partnership with Theradaptive, acquiring exclusive U.S. distribution rights for OsteoAdapt®. The company mourned the passing of Board Member Jeffrey P. Rydin.

Information regarding the specific demand seasonality for Alphatec Holdings, Inc.'s products and services is not readily available in the provided search results. One source indicated that access to seasonal trends requires a premium account.

Alphatec Holdings, Inc. (ATEC), headquartered in Carlsbad, California, is a medical technology company focused on revolutionizing spine surgery through innovative solutions for spinal disorders. The company designs, develops, manufactures, and markets a comprehensive portfolio of spine hardware, biologics, and instruments. Its major products include the Alpha InformatiX platform, which integrates technologies like the EOS imaging system, VEA alignment mobile application, SafeOp Neural InformatiX System, and Valence intra-operative system. Alphatec also offers Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems, split-blade retractors, and the Sigma-ALIF Access System. Its spinal implants and fixation systems feature products like NanoTec and Invictus, alongside various standalone implants. Furthermore, Alphatec provides a range of biologics, including 3D ProFuse Osteoconductive Bioscaffold, AlphaGRAFT Demineralized Bone Matrix (DBM), BioCORE Moldable Bioactive Graft, AlphaGRAFT DBM Fibers, AlphaGRAFT Cellular Bone Matrix (CBM), and Amnioshield Amniotic Tissue Barrier.

Alphatec Holdings, Inc. is headquartered in Carlsbad, California. The company has a significant market presence across North America and Europe. It is also in the early stages of international expansion, focusing on select markets such as Australia, New Zealand, and Japan.

Alphatec Holdings, Inc. maintains a positive brand reputation within the medical technology sector, driven by its focus on innovation and surgeon education. Analyst sentiment towards Alphatec is overwhelmingly positive, with a consensus of "Moderate Buy" and a high percentage of "Strong Buy" ratings. No specific events negatively impacting Alphatec Holdings, Inc.'s brand reputation in the past year were found in the search results.

Alphatec Holdings, Inc. has a diverse ownership structure. Institutional investors hold a significant portion of the company's shares, with 425 institutional owners holding a total of 121,999,914 shares. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, American Century Companies Inc, UBS Group AG, Royal Bank Of Canada, and Deutsche Bank Ag. Squadron Capital, LLC is noted as a large shareholder with 11% of shares outstanding, and LS Power Development, LLC and BlackRock, Inc. are also significant holders. Overall, institutional ownership accounts for approximately 69.4% of the company, while individuals hold about 11.7%. Insiders collectively own 22.8% of the company, with CEO Patrick Miles owning 3.6% of the shares.